This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fairfield, W. P. Articles by Grinspoon, S. K. Search for Related Content PubMed PubMed Citation Articles by Fairfield, W. P. Articles by Grinspoon, S. K.

Osteopenia in Eugonadal Men with Acquired Immune Deficiency Syndrome Wasting Syndrome¹

Neuroendocrine Unit (W.F., A.K., S.G.) and Endocrine Unit (J.F.), Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114

Address all correspondence and requests for reprints to: Steven Grinspoon, M.D., Neuroendocrine Unit, Bulfinch 457B, Massachusetts General Hospital, Boston, Massachusetts 02114. E-mail: sgrinspoon{at}partners.org

Multiple endocrine and metabolic consequences of human immunodeficiency virus (HIV) infection exist that may contribute to bone loss in men with the acquired immune deficiency syndrome (AIDS) wasting syndrome. Recent studies suggest that anabolic strategies can increase lean body mass in men with AIDS wasting. Prior studies have not examined the effects of anabolic agents on bone mineral density (BMD) or bone turnover in these men. To determine the effects of testosterone and progressive resistance training on BMD and bone turnover in eugonadal men with AIDS wasting, we randomly assigned 54 eugonadal men with AIDS wasting (weight <90% IBW or weight loss >10% from preillness baseline) to receive either testosterone enanthate (200 mg/week, im) or placebo and to progressive resistance training (3 times/week) or no training in a 2 x 2 factorial study design for 3 months. The BMD of the lumbar spine, proximal femur, and total body; lean body mass; and fat mass were measured by dual energy x-ray absorptiometry. Total body scans were repeated after 12 weeks of therapy. Baseline bone turnover and BMD were compared with those in 35 age-matched healthy non-HIV-infected control subjects.

Compared with controls, lumbar spine BMD (1.021 ± 0.018 vs. 1.084 ± 0.025 g/cm²; P = 0.04) and total hip BMD (0.951 ± 0.017 vs. 1.070 ± 0.019 g/cm²; P < 0.0001) were reduced in men with AIDS wasting. T-scores were lower in men with AIDS wasting at the lumbar spine (-0.62 ± 0.17 vs. -0.07 ± 0.23, P = 0.05) and total hip (-0.65 ± 0.11 vs. +0.20 ± 0.014, P < 0.0001). Total hip T scores were less than -1.0 in 33% of men with AIDS wasting. Neither the use of protease inhibitors nor the duration of protease inhibitors use correlated with BMD. Serum osteocalcin levels were lower (3.63 ± 0.29 vs. 4.54 ± 0.31 nmol/L; P < 0.04) and urinary N-telopeptide excretion was higher (45.4 ± 4.5 vs. 26.8 ± 3.0 nmol BCE/mmol creatinine; P = 0.004) in men with AIDS wasting than in controls.

Lumbar spine BMD, as assessed on regional total body dual energy x-ray absorptiometry scan, increased over the 12-week treatment period in response to testosterone (+2.4 ± 1.3 vs. -1.3 ± 1.0%, testosterone vs. placebo, respectively; P = 0.02), but not in response to training (+0.8 ± 1.0 vs. +0.4 ± 1.3%, training vs. no training; P = 0.70).

Lumbar spine and total hip BMD are reduced in eugonadal men with AIDS wasting. Biochemical markers of bone turnover suggest that bone formation and bone resorption are uncoupled in these men. Testosterone administration, but not resistance training, over 3 months increases lumbar spine BMD in eugonadal men with AIDS wasting.

This article has been cited by other articles:

				M. T. Yin, D. J. McMahon, D. C. Ferris, C. A. Zhang, A. Shu, R. Staron, I. Colon, J. Laurence, J. F. Dobkin, S. M. Hammer, et al. Low Bone Mass and High Bone Turnover in Postmenopausal Human Immunodeficiency Virus-Infected Women J. Clin. Endocrinol. Metab., February 1, 2010; 95(2): 620 - 629. [Abstract] [Full Text] [PDF]

				E. Pollock, A.-E. Klotsas, J. Compston, and E. Gkrania-Klotsas Bone health in HIV infection Br. Med. Bull., December 1, 2009; 92(1): 123 - 133. [Abstract] [Full Text] [PDF]

				P. G Clay, L. E Voss, C. Williams, and E. C Daume Valid Treatment Options for Osteoporosis and Osteopenia in HIV-Infected Persons Ann. Pharmacother., May 1, 2008; 42(5): 670 - 679. [Abstract] [Full Text] [PDF]

				M. J. Bolland, A. B. Grey, G. D. Gamble, and I. R. Reid Low Body Weight Mediates the Relationship between HIV Infection and Low Bone Mineral Density: A Meta-Analysis J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4522 - 4528. [Abstract] [Full Text] [PDF]

				M. J. Tracz, K. Sideras, E. R. Bolona, R. M. Haddad, C. C. Kennedy, M. V. Uraga, S. M. Caples, P. J. Erwin, and V. M. Montori Testosterone Use in Men and Its Effects on Bone Health. A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2011 - 2016. [Abstract] [Full Text] [PDF]

				P. Koutkia, B. Canavan, J. Breu, and S. Grinspoon Effects of Growth Hormone-Releasing Hormone on Bone Turnover in Human Immunodeficiency Virus-Infected Men with Fat Accumulation J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2154 - 2160. [Abstract] [Full Text] [PDF]

				G. A. McComsey, J. S. Huang, I. J. Woolley, B. Young, P. E. Sax, M. Gerber, S. Swindells, H. Bonilla, and G. Gopalakrishnan Fragility Fractures in HIV-Infected Patients: Need for Better Understanding of Diagnosis and Management J Int Assoc Physicians AIDS Care (Chic Ill), July 1, 2004; 3(3): 86 - 91. [Abstract] [PDF]

				S. Mora, I. Zamproni, S. Beccio, R. Bianchi, V. Giacomet, and A. Vigano Longitudinal Changes of Bone Mineral Density and Metabolism in Antiretroviral-Treated Human Immunodeficiency Virus-Infected Children J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 24 - 28. [Abstract] [Full Text] [PDF]

				G. Van den Berghe, D. Van Roosbroeck, P. Vanhove, P. J. Wouters, L. De Pourcq, and R. Bouillon Bone Turnover in Prolonged Critical Illness: Effect of Vitamin D J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4623 - 4632. [Abstract] [Full Text] [PDF]

				P. G Clay and A. I Lam Testosterone Replacement Therapy for Bone Loss Prevention in HIV-Infected Males Ann. Pharmacother., April 1, 2003; 37(4): 582 - 585. [Abstract] [Full Text] [PDF]

				M. Peacock, C. H. Turner, M. J. Econs, and T. Foroud Genetics of Osteoporosis Endocr. Rev., June 1, 2002; 23(3): 303 - 326. [Abstract] [Full Text] [PDF]

				D. M. Gaughan, L. M. Mofenson, M. D. Hughes, G. R. Seage III, G. L. Ciupak, and J. M. Oleske Osteonecrosis of the Hip (Legg-Calve-Perthes Disease) in Human Immunodeficiency Virus-Infected Children Pediatrics, May 1, 2002; 109(5): e74 - 74. [Abstract] [Full Text] [PDF]